NYSE:BHVN - Biohaven Pharmaceutical Holding Company Ltd.
$45.72
 $3.20
+7.53%
4:00PM EDT
2019-07-15
Biohaven Pharmaceutical Holding Company Ltd., incorporated on September 25, 2013, is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.The Company is developing rimegepant as an orally available, selective and potent small molecule CGRP receptor antagonist for the acute treatment of migraine. The rimegepant CGRP receptor antagonist for the treatment of migraine with the ability to address important unmet needs, such as durable efficacy across all four traditional migraine symptoms and reduced incidence of headache recurrence, without contraindications or warnings in patients with cardiovascular disease or cardiovascular risk factors such as hypertension.. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BHVN     avg for
industry  
  avg for
sector  
42 stocks weight:  57. 59   114. 77   204. 78  
42 stocks rank:  2. 14 K 1. 44 K 810. 33  
# analyst opinions:  9. 00   13. 59   13. 86  
mean recommendation:  1. 70   2. 12   2. 04  

quick ratio:  9. 18   5. 48   1. 89  
current ratio:  9. 60   5. 85   2. 40  

target price low:  57. 00   82. 72   115. 11  
target price avg:  77. 44   104. 42   138. 02  
target price high:  100. 00   130. 64   159. 47  
1-yr high:  67. 01   110. 27   142. 72  
last close:  42. 52   85. 12   126. 54  
50-day avg:  53. 92   86. 06   122. 35  
200-day avg:  44. 99   88. 76   121. 75  
1-yr low:  29. 75   69. 26   100. 63  
volume:  1. 18 M 3. 51 M 5. 53 M
50-day avg volume:  1. 07 M 3. 21 M 4. 22 M
200-day avg volume:  636. 64 K 3. 04 M 4. 75 M

1-day return:  -1. 32 % -0. 30 % -1. 01 %
this week return:  -0. 93 % -2. 16 % -1. 35 %
12-wk return:  -29. 32 % 3. 34 % 8. 69 %
52-wk return:  4. 95 % -1. 76 % 12. 22 %

enterprise value (EV):  1. 72 B 46. 50 B 123. 99 B
market cap:  2. 19 B 40. 77 B 109. 11 B
EBITDA:  -195. 27 M 4. 33 B 8. 19 B
enterprise multiple (EV/EBITDA):  -8. 82   5. 45   12. 05  
total debt:  0. 00   11. 27 B 17. 58 B
net income (common):  -217. 76 M 2. 13 B 4. 27 B

shares outstanding:  44. 28 M 551. 08 M 1. 24 B
shares:  35. 29 M 559. 41 M 1. 22 B
shares short:  4. 37 M 11. 15 M 11. 94 M
shares short prior month:  3. 79 M 9. 31 M 11. 96 M
short ratio:  8. 38   5. 72   3. 43  
short % of float:  12. 28 % 6. 40 % 2. 65 %
total cash/share:  4. 90   11. 00   9. 23  
total cash:  217. 41 M 6. 03 B 6. 01 B
free cash flow:  -109. 59 M 3. 02 B 4. 96 B
operating cash flow:  -162. 48 M 3. 92 B 5. 99 B

book value:  2. 19   13. 02   27. 49  
price/book:  19. 41   4. 21   8. 80  
gross profits:  -108. 46 M 7. 67 B 36. 29 B
operating margins:  0. 00 % -380. 20 % -38. 44 %
EBITDA margins:  0. 00 % 13. 59 % 23. 24 %
profit margins:  0. 00 % 10. 94 % 14. 00 %
gross margins:  0. 00 % 36. 11 % 55. 16 %

1-yr max volatility:  25. 37 % --- ---
1-yr mean volatility:  2. 87 % 1. 50 % 1. 08 %

1-yr EPS:  -5. 30   2. 12   4. 26  
forward EPS:  -5. 07   3. 47   7. 14  
P/E:  -8. 02   2. 15   33. 17  
forward P/E:  -8. 50   -4. 03   17. 60  
PE/G:  1. 02   0. 54   0. 34  
growth:  -7. 88 % 263. 03 % 78. 34 %
earnings high:  -1. 09   0. 91   1. 70  
earnings avg:  -1. 81   0. 71   1. 58  
earnings low:  -4. 07   0. 48   1. 46  
revenue high:  -0. 00   2. 64 B 11. 26 B
revenue avg:  -0. 00   2. 58 B 11. 09 B
revenue low:  -0. 00   2. 54 B 10. 90 B
return on assets:  -65. 86 % -2. 31 % 5. 31 %
return on equity:  -212. 63 % -82. 48 % 135. 30 %

beta (1yr vs S&P500):  1. 81   1. 26   0. 91  
sharpe (1yr):  0. 37   0. 07   0. 77  

held % insiders:  19. 97 % 6. 08 % 3. 31 %
held % institutions:  91. 92 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : BHVN
.    145.299 =       145.299 :: --> INITIAL WEIGHT <--
.    - 5.305 =       139.994 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.     x 2.16 =       302.379 :: P/E factor
.    x 0.998 =       301.897 :: PE/G factor
.    x 1.655 =       499.578 :: beta factor
.    x 0.771 =        385.28 :: sharpe factor
.    x 2.361 =        909.47 :: current ratio factor
.    x 1.059 =       963.484 :: quick ratio factor
.    x 1.058 =      1019.352 :: short ratio factor
.    x 1.165 =      1188.041 :: price-to-book factor
.                               --> PERFORMANCE <--
.    x 2.114 =      2511.501 :: sector+industry 1-year gains factor
.    x 1.033 =       2595.38 :: industry 12-weeks return factor
.    x 1.305 =      3387.681 :: industry 2-weeks return factor
.    x 1.021 =      3458.444 :: company one-year gains+dividend factor
.    x 2.583 =      8933.885 :: company 13 weeks' performance factor
.    x 1.199 =     10708.011 :: 50-day avg > 200-day avg
.    / 2.054 =       5212.04 :: overall "drift" factor
.    x 0.586 =      3055.712 :: largest single-day jump factor
.     x 0.99 =      3023.821 :: volatility factor
.    x 0.988 =      2987.502 :: 42-day volatility factor
.    x 4.022 =     12015.385 :: notable returns + performance factor
.    x 2.287 =     27481.149 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.596 =     16391.696 :: forward EPS factor
.    x 0.853 =     13988.106 :: forward P/E factor
.    x 1.182 =      16540.22 :: industry recommendation factor
.    x 2.731 =     45169.149 :: company recommendation factor
.    x 1.008 =     45514.618 :: factor historical industry gain for week 28
.    x 1.724 =     78468.876 :: target low factor
.    x 1.302 =    102172.605 :: target mean factor
.    x 1.049 =    107161.973 :: target high factor
.   x 11.277 =   1208486.866 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        33.156 :: reduced for readability
.   + 24.433 =        57.589 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     57.589 :: FINAL WEIGHT for NYSE:BHVN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org